Compare Boston Scientific Corporation (BSX) vs Hormel Foods Corp (HRL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Boston Scientific Corporation vs Hormel Foods Corp — how do they compare? Boston Scientific Corporation trades at $43.55 (market cap $66.37B), while Hormel Foods Corp trades at $25.47 (market cap $13.65B). The key difference: Boston Scientific Corporation is far larger — about 4.9× Hormel Foods Corp's market cap, and Hormel Foods Corp pays a 4.72% dividend while Boston Scientific Corporation pays none. Which is the better fit depends on your goals.
| BSX | HRL | |
|---|---|---|
Market Cap | $66.37B | $13.65B |
Sector | Health | Consumer Staples |
52-Week High | $108.14 | $29.91 |
52-Week Low | $42.63 | $19.74 |
Enterprise Value | $75.94B | $15.65B |
Dividend Yield | — | 4.72% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Boston Scientific (BSX) trades at $44.65, down 0.27% with bearish technical signals despite strong fundamentals. The company delivered three consecutive earnings beats with Q3-Q1 2026 EPS exceeding expectations, while revenue grew to $20.07B in 2025 with improving profit margins. Technical indicators show bearish momentum with support at $44 and resistance at $45, though Wall Street maintains 88% buy rating with $70.20 consensus target.
BSX presents a compelling value opportunity with attractive valuation multiples (P/E 18.68, P/S 3.24) and robust financial health, though near-term headwinds include competitive pressures in key segments and recent stock price decline of nearly 60% from 2025 highs. The strong analyst consensus suggests significant upside potential if execution improves.
Hormel Foods (HRL) trades at $24.46, down 1.11% on the day, with a neutral technical outlook and mixed analyst sentiment. The company has beaten earnings estimates for three consecutive quarters, though net income margin has compressed to 3.82% in 2025 from 6.75% in 2024. Recent strategic moves include the sale of its Brazilian Ceratti operations to focus on higher-growth markets, while maintaining its Dividend King status with 60 consecutive years of dividend increases.
The stock presents a value opportunity with a P/E of 28.78 and consensus price target of $26.33 (7.6% upside), but faces margin pressure from input cost inflation and competitive headwinds. The dividend yield of approximately 4.7% provides income support, though earnings stabilization remains key for sustained recovery from multi-year lows.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Boston Scientific Corporation
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
Read more on BSX →About Hormel Foods Corp
Hormel Foods is a protein-focused branded food company. Its brands include its namesake Hormel, Spam, Jennie-O, Dinty Moore, Applegate, Wholly Guacamole, and Skippy. The vast majority of the company's revenue is U.S.-based: 64% U.S. retail, 28% U.S. food service, and 8% international. By product type, in fiscal 2021, 23% of revenue was shelf-stable foods, 18% was poultry (branded and commodity), 55% was other perishable food, and 3% was other, primarily nutritional products. The company holds the number-one market position in shelf-stable meat, shelf-stable ready meals, pepperoni, natural/organic deli meat, and guacamole and the number-two position in turkey, bacon, chilled ready meals, and peanut butter.
Read more on HRL →
